U.S. Biopharmaceuticals Contract Manufacturing Market Size, Statistics 2033 Report

In the rapidly growing field of the U.S. biopharmaceuticals contract manufacturing Market size was valued at USD 5.19 billion in 2023 and is projected to reach USD 7.83 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033 according to a new report by Nova One Advisor.

With a perpetual expansion of the biopharmaceutical industry, companies are facing production issues, such as the need for more expertise and sophisticated equipment while practicing in-house manufacturing. The maturity of biotechnology and the availability of external funding has resulted in growth of several early-stage bio/pharma companies. These companies are recognized as core customers of CMOs, as these organizations lack the capabilities to develop robust manufacturing operations.

The market is witnessing lucrative growth owing to rising R&D spending for the biologic’s development coupled with the presence of large number of FDA approved drugs in the country. U.S. is hosting many biopharmaceutical pipeline in various stages of development. More than 900 biologic molecules are under clinical investigation in the country. Steady growth in the number of new biological approvals in the country is anticipated to boost revenue generation for the market.

Increasing adoption and investment in advanced manufacturing technologies by CMOs based in the U.S. is propelling the market growth. In addition, quality services offered by service providers are driving the biopharma and CMO partnerships in the country. Also, expansion of foreign CMOs and CROs into the country is expected to propel the market growth.

Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)?@ https://www.novaoneadvisor.com/report/sample/8434

?Key Takeaways:

• The mammalian source segment accounted for the highest share of 56.19% in 2023.
• The non-mammalian segment is anticipated to witness the fastest CAGR during the forecast period.
• Process development services led the market in 2023 and accounted for a share of 32.11%.
• The analytical & QC studies segment is anticipated to witness the fastest CAGR from 2024 to 2033.
• The biologics product segment led the market in 2023, with a share of over 81.18%.
• The biosimilar segment is expected to witness a significant growth from 2024 to 2033.

U.S. Biopharmaceuticals Contract Manufacturing Market Recent Developments

• In May 2023, Aurigene Pharmaceutical Services Limited, a biopharmaceutical CDMO, announced the construction of a state-of-the-art manufacturing and development facility for therapeutic proteins, viral vectors, and antibodies.
• In June 2022, FUJIFILM Corporation acquired cell therapy manufacturing facility from Atara Biotherapeutics, Inc. This acquisition expands its CDMO capability for production of cell therapies for clinical and commercial purposes.
• In April 2022, Lonza extended the capability of its Coccon platform used in the manufacturing of automated cell therapy. The new capabilities included integrated capabilities in cell separation, cell binding, and bead removal.
• In March 2022, Cambrex, expanded its biopharmaceutical testing services business with the addition of 11 cGMP laboratories in its U.S. facility. The expansion included the addition of instruments for nanoparticle size analysis, qPCR, imaging, mass spectrometry, immunoblotting, and next-generation sequencing, as well as for other applications.
• In February 2022, Thermo Fisher Scientific, Inc. invested $40 million to build a bioprocessing manufacturing site in Millersburg, Pennsylvania for developing critical vaccines and biologics.

Key U.S. Biopharmaceuticals Contract Manufacturing Company Insights

The companies in U.S. biopharmaceuticals contract manufacturing market are focused on the expansion of their manufacturing capabilities as well as establishing new services to meet the growing demand of biopharmaceutical companies. Along with small players, these entities are also engaged in a partnership with established biopharma companies. All the major biopharmaceutical firms have a wide-ranging product pipeline and are investing in developing new products.

Key U.S. Biopharmaceuticals Contract Manufacturing Companies:

• Lonza
• WuXi Biologics
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Boehringer Ingelheim
• Thermo Fisher Scientific Inc.
• Samsung BioLogics
• AGC Biologics
• Catalent Pharma Solutions
• Rentschler Biopharma SE
• Eurofins Scientific SE

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Biopharmaceuticals Contract Manufacturing market.

By Source?

• Mammalian
• Non-mammalian

By Service?

• Process Development, Downstream ,Upstream
• Fill & Finish Operations
• Analytical & QC studies
• Packaging

By Product?

• Biologics ,Monoclonal antibodies (MABs) ,Recombinant Proteins, Vaccines Antisense, RNAi, & Molecular Therapy Others
• Biosimilar

?Table of Contents

• Market Summary
• Economic Impact Competition Analysis by Players
• Production, Revenue (Value) by geographical segmentation
• Kinesiology Muscle Tape Market Size by Type and Application
• Regional Market Status and Outlook
• Kinesiology Muscle Tape Market Analysis and Outlook
• Market Forecast by Region, Type, and Application
• Cost Investigation, Market Dynamics
• Marketing Strategy comprehension, Distributors and Traders
• Market Effect Factor Analysis
• Research Finding/ Conclusion
• Appendix
• Continue……

Highlight the Following Key Factors:

• Business Description:?a particular description of agency operations and enterprise departments.
• Company Strategy:?The analyst’s precis of the company’s commercial enterprise strategy.
• SWOT Analysis:?Detailed evaluation of the company’s strengths, weaknesses, opportunities, and threats.
• Company History:?The development of predominant occasions associated to the company.
• Main merchandise and services:?A listing of the company’s fundamental products, services, and brands.
• Main Competitors:?A listing of the company’s fundamental competitors.
• Important places and subsidiaries:?The company’s major places and subsidiaries’ listing and contact information.
• Detailed economic ratios of the previous 5 years:?The trendy monetary ratios come from the annual economic statements issued by means of agencies with a record of 5 years.

?Immediate Delivery Available | Buy This Premium Research: https://www.novaoneadvisor.com/report/checkout/8434

Unlocking Market Insights through Data Excellence

The "Precedence Statistics" flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today's dynamic and data-driven world.

?Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with US

• Apt 1408 1785 RiversideDrive Ottawa, ON, K1G 3T7, Canada
• 2nd Floor, Shreeleela Plaza, Baner Road,Pune, Maharashtra - 411045
• USA - +1 9197 992 333 IND - +91 93077 85324
• [email protected]

Web: https://www.novaoneadvisor.com/

Blog: https://www.precedenceresearch.com/

Blog:? https://www.visionresearchreports.com/